« Return to News | Awards & Advancement

BioStat’s rED Cap software receives trademark status

Thursday, February 2, 2012 09:02 AM

BioStat International’s rED Cap, proprietary, web-based clinical trial data management software, has received trademark status. This distinction follows the October 2011 rollout of rED Cap during the BioFlorida Annual Conference.

Thanks to its navigation and usage-based, zero-licensing pricing model, rED Cap has received strong accolades in its first few months of release.

For multi-site clinical research trials, pharmaceutical research, development and marketing and medical observational studies, rED Cap provides a comprehensive Web-based data management solution to collect and store data, all in a secure environment (rED Cap meets compliance requirements for both HIPAA and CFR21 Part 11).

To support quality research, rED Cap also features a customizable electronic case report form, flexible workflow, dynamic reporting and data status and powerful data validation capability. BSI data management CRO service—offered with each rED Cap study—can provide assistance to a research team in efficient project management and experienced data analysis for meeting study objectives.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.